Leading edge: intratumor delivery of monoclonal antibodies for the treatment of solid tumors

Immunotherapies based on immune checkpoint blockade have shown remarkable clinical outcomes and durable responses in patients with many tumor types. Nevertheless, these therapies lack efficacy in most cancer patients, even causing severe adverse events in a small subset of patients, such as inflamma...

Descripción completa

Detalles Bibliográficos
Autores: Blanco, Ester, Chocarro de Erauso, Luisa, Fernández Rubio, Leticia, Bocanegra Gondán, Ana Isabel, Arasanz Esteban, Hugo, Echaide Górriz, Míriam, Garnica, Maider, Piñeiro Hermida, Sergio, Kochan, Grazyna, Escors Murugarren, David
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Universidad Pública de Navarra
Repositorio:Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
OAI Identifier:oai:academica-e.unavarra.es:2454/46008
Acceso en línea:https://hdl.handle.net/2454/46008
Access Level:acceso abierto
Palabra clave:Intratumoral therapy
Monoclonal antibodies (mAbs)
Non-viral therapy
Viral therapy
id ES_2b90d2e6cbf2f5731270cda5e244a31a
oai_identifier_str oai:academica-e.unavarra.es:2454/46008
network_acronym_str ES
network_name_str España
repository_id_str
spelling Leading edge: intratumor delivery of monoclonal antibodies for the treatment of solid tumorsBlanco, EsterChocarro de Erauso, LuisaFernández Rubio, LeticiaBocanegra Gondán, Ana IsabelArasanz Esteban, HugoEchaide Górriz, MíriamGarnica, MaiderPiñeiro Hermida, SergioKochan, GrazynaEscors Murugarren, DavidIntratumoral therapyMonoclonal antibodies (mAbs)Non-viral therapyViral therapyImmunotherapies based on immune checkpoint blockade have shown remarkable clinical outcomes and durable responses in patients with many tumor types. Nevertheless, these therapies lack efficacy in most cancer patients, even causing severe adverse events in a small subset of patients, such as inflammatory disorders and hyper-progressive disease. To diminish the risk of developing serious toxicities, intratumor delivery of monoclonal antibodies could be a solution. Encouraging results have been shown in both preclinical and clinical studies. Thus, intratumor immunotherapy as a new strategy may retain efficacy while increasing safety. This approach is still an exploratory frontier in cancer research and opens up new possibilities for next-generation personalized medicine. Local intratumor delivery can be achieved through many means, but an attractive approach is the use of gene therapy vectors expressing mAbs inside the tumor mass. Here, we summarize basic, translational, and clinical results of intratumor mAb delivery, together with descriptions of non-viral and viral strategies for mAb delivery in preclinical and clinical development. Currently, this is an expanding research subject that will surely play a key role in the future of oncology.The OncoImmunology group is funded by the Spanish Association against Cancer (AECC) (grant number PROYE16001ESCO); Instituto de Salud Carlos III (ISCIII)-FEDER project grants (grant numbers FIS PI17/02119, FIS PI20/00010, COV20/00000, TRANSPOCART ICI19/00069); a Biomedicine Project grant from the Department of Health of the Government of Navarre (grant number BMED 050-2019); strategic projects from the Department of Industry, Government of Navarre (AGATA, Ref. 0011-1411-2020-000013; LINTERNA, Ref. 0011-1411-2020-000033; DESCARTHES, 0011-1411-2019-000058); European Project Horizon 2020 Improved Vaccination for Older Adults (ISOLDA; ID: 848166). Crescendo Biologics Ltd. supported the OncoImmunology group for the development and testing of PD-1 and LAG-3 bispecific antibodies.MDPICiencias de la SaludOsasun Zientziak2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/2454/46008reponame:Academica-e. Repositorio Institucional de la Universidad Pública de Navarrainstname:Universidad Pública de NavarraInglésinfo:eu-repo/grantAgreement/European Commission/Horizon 2020 Framework Programme/848166info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI17%2F02119info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI20%2F00010info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/ICI19%2F00069info:eu-repo/grantAgreement/Gobierno de Navarra//050-2019info:eu-repo/grantAgreement/Gobierno de Navarra//0011-1411-2020-000013info:eu-repo/grantAgreement/Gobierno de Navarra//0011-1411-2020-000033info:eu-repo/grantAgreement/Gobierno de Navarra//0011-1411-2019-000058© 2023 by the authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:academica-e.unavarra.es:2454/460082026-06-17T12:41:47Z
dc.title.none.fl_str_mv Leading edge: intratumor delivery of monoclonal antibodies for the treatment of solid tumors
title Leading edge: intratumor delivery of monoclonal antibodies for the treatment of solid tumors
spellingShingle Leading edge: intratumor delivery of monoclonal antibodies for the treatment of solid tumors
Blanco, Ester
Intratumoral therapy
Monoclonal antibodies (mAbs)
Non-viral therapy
Viral therapy
title_short Leading edge: intratumor delivery of monoclonal antibodies for the treatment of solid tumors
title_full Leading edge: intratumor delivery of monoclonal antibodies for the treatment of solid tumors
title_fullStr Leading edge: intratumor delivery of monoclonal antibodies for the treatment of solid tumors
title_full_unstemmed Leading edge: intratumor delivery of monoclonal antibodies for the treatment of solid tumors
title_sort Leading edge: intratumor delivery of monoclonal antibodies for the treatment of solid tumors
dc.creator.none.fl_str_mv Blanco, Ester
Chocarro de Erauso, Luisa
Fernández Rubio, Leticia
Bocanegra Gondán, Ana Isabel
Arasanz Esteban, Hugo
Echaide Górriz, Míriam
Garnica, Maider
Piñeiro Hermida, Sergio
Kochan, Grazyna
Escors Murugarren, David
author Blanco, Ester
author_facet Blanco, Ester
Chocarro de Erauso, Luisa
Fernández Rubio, Leticia
Bocanegra Gondán, Ana Isabel
Arasanz Esteban, Hugo
Echaide Górriz, Míriam
Garnica, Maider
Piñeiro Hermida, Sergio
Kochan, Grazyna
Escors Murugarren, David
author_role author
author2 Chocarro de Erauso, Luisa
Fernández Rubio, Leticia
Bocanegra Gondán, Ana Isabel
Arasanz Esteban, Hugo
Echaide Górriz, Míriam
Garnica, Maider
Piñeiro Hermida, Sergio
Kochan, Grazyna
Escors Murugarren, David
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Ciencias de la Salud
Osasun Zientziak
dc.subject.none.fl_str_mv Intratumoral therapy
Monoclonal antibodies (mAbs)
Non-viral therapy
Viral therapy
topic Intratumoral therapy
Monoclonal antibodies (mAbs)
Non-viral therapy
Viral therapy
description Immunotherapies based on immune checkpoint blockade have shown remarkable clinical outcomes and durable responses in patients with many tumor types. Nevertheless, these therapies lack efficacy in most cancer patients, even causing severe adverse events in a small subset of patients, such as inflammatory disorders and hyper-progressive disease. To diminish the risk of developing serious toxicities, intratumor delivery of monoclonal antibodies could be a solution. Encouraging results have been shown in both preclinical and clinical studies. Thus, intratumor immunotherapy as a new strategy may retain efficacy while increasing safety. This approach is still an exploratory frontier in cancer research and opens up new possibilities for next-generation personalized medicine. Local intratumor delivery can be achieved through many means, but an attractive approach is the use of gene therapy vectors expressing mAbs inside the tumor mass. Here, we summarize basic, translational, and clinical results of intratumor mAb delivery, together with descriptions of non-viral and viral strategies for mAb delivery in preclinical and clinical development. Currently, this is an expanding research subject that will surely play a key role in the future of oncology.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2454/46008
url https://hdl.handle.net/2454/46008
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv info:eu-repo/grantAgreement/European Commission/Horizon 2020 Framework Programme/848166
info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (ISCIII)/PI17%2F02119
info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI20%2F00010
info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/ICI19%2F00069
info:eu-repo/grantAgreement/Gobierno de Navarra//050-2019
info:eu-repo/grantAgreement/Gobierno de Navarra//0011-1411-2020-000013
info:eu-repo/grantAgreement/Gobierno de Navarra//0011-1411-2020-000033
info:eu-repo/grantAgreement/Gobierno de Navarra//0011-1411-2019-000058
dc.rights.none.fl_str_mv https://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
instname:Universidad Pública de Navarra
instname_str Universidad Pública de Navarra
reponame_str Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
collection Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869405157022760960
score 15,812429

Similares en LA Referencia